Patents Assigned to Ablynx N.V.
  • IMMUNOGLOBULIN VARIABLE DOMAINS
    Publication number: 20210269515
    Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which a is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
    Type: Application
    Filed: March 29, 2021
    Publication date: September 2, 2021
    Applicant: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • IMMUNOGLOBULIN VARIABLE DOMAINS
    Publication number: 20210269514
    Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
    Type: Application
    Filed: March 29, 2021
    Publication date: September 2, 2021
    Applicant: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • IMMUNOGLOBULIN VARIABLE DOMAINS
    Publication number: 20210261653
    Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
    Type: Application
    Filed: March 29, 2021
    Publication date: August 26, 2021
    Applicant: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • NOVEL ANTIGEN BINDING DIMER-COMPLEXES, METHODS OF MAKING/AVOIDING AND USES THEREOF
    Publication number: 20210246192
    Abstract: In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomeric counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided.
    Type: Application
    Filed: January 5, 2021
    Publication date: August 12, 2021
    Applicant: Ablynx N.V.
    Inventors: Ann Brigé, Christine Labeur, Marc Jozef Lauwereys
  • IMPROVED IMMUNOGENICITY ASSAYS
    Publication number: 20210239709
    Abstract: The present invention relates to improved immunogenicity assays and methods for performing the same. In particular, the present invention relates to improved immunogenicity assays that are capable of distinguishing neutralizing anti-drug antibodies from non-neutralizing anti-drug antibodies. More in particular, the present invention relates to improved immunogenicity assays that allow (amounts and/or concentrations of) neutralizing anti-drug antibodies to be detected and/or measured in a sample even in the presence of non-neutralizing anti-drug antibodies.
    Type: Application
    Filed: March 29, 2018
    Publication date: August 5, 2021
    Applicant: Ablynx N.V.
    Inventors: Annelies Coddens, Veerle Snoeck, Marie-Ange Buyse, Carlo Boutton
  • Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
    Patent number: 11078290
    Abstract: The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: August 3, 2021
    Assignee: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Sigrid Cornelis, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • METHODS OF TREATING INITIAL EPISODE OF TTP WITH IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    Publication number: 20210221912
    Abstract: The present invention is based on the finding that administration of polypeptides comprising two immunoglobulin single variable domains (ISVD) against von Willebrand Factor (vWF) to human patients with an initial episode of thrombotic thrombocytopenic purpura (TTP) episode results in improved outcomes, including a faster time to platelet count response lower proportion of patients with either death, recurrence or a major thromboembolic event (TE) during the treatment period, lower recurrence rate, and prevention of refractoriness. The invention provides a polypeptide comprising two ISVD against vWF for use in treating a vWF-related disease, preferably TTP, in a human in need thereof. The invention further relates to dosage unit forms, kits and medical uses for treating TTP.
    Type: Application
    Filed: February 6, 2019
    Publication date: July 22, 2021
    Applicant: Ablynx N.V.
    Inventors: Filip Callewaert, Hilde De Winter
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20210214431
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: March 22, 2021
    Publication date: July 15, 2021
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernhard Weigle, Klaus Erb
  • Polypeptides that bind glucocorticoid-induced TNFR family-related receptor (GITR)
    Patent number: 11059899
    Abstract: The present invention relates to immunoglobulin single variable domains that bind GITR and more in particular to polypeptides that comprise or essentially consist of one or more such immunoglobulin single variable domains; to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the polypeptides of the present invention enhance the biological activity of GITR.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: July 13, 2021
    Assignee: Ablynx N.V.
    Inventors: Pieter Deschaght, Sandra Li, Veerle Snoeck, Jan Pype
  • T cell recruiting polypeptides based on CD3 reactivity
    Patent number: 11046767
    Abstract: T cell recruiting polypeptides are provided that bind CD3 on a T cell. The polypeptides can be used in methods for treatment of cancers.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: June 29, 2021
    Assignee: Ablynx N.V.
    Inventors: Annelies Roobrouck, Diane Van Hoorick, João Vieira
  • Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
    Patent number: 11046773
    Abstract: The present invention relates to bispecific polypeptides that are directed against the cellular receptor CD4 as well as a cellular co-receptor for HIV. Said polypeptides may be used to prevent human cell entry of HIV.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: June 29, 2021
    Assignee: Ablynx N.V.
    Inventors: Hugo Soares, Dominique Schols, Peter Vanlandschoot, Philippe Van Rompaey, Catelijne Stortelers
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFA AND OX40L
    Publication number: 20210188986
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an autoimmune or inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to TNF? and at least two ISVDs binds to OX4OL. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: December 4, 2020
    Publication date: June 24, 2021
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Peter Florian, Karen Heyninck, Thomas Kreutzberg, Thomas Leeuw, Eric Lorent, Oezen Sercan Alp, Gertrud Sibenhorn
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFA AND IL-23
    Publication number: 20210188963
    Abstract: The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF? and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: December 4, 2020
    Publication date: June 24, 2021
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
  • POLYPEPTIDES AGAINST IL-23
    Publication number: 20210188967
    Abstract: The present invention relates to amino acid sequences that are directed against IL-23. The amino acid sequences of the present invention comprise two Nanobodies against IL-23 and one Nanobody against serum albumin, linked by two linkers (9GS linkers). In particular, the invention relates to the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3 (listed in Table 1 and FIG. 1) (also referred to herein as “anti-IL 23 polypeptides of the invention”).
    Type: Application
    Filed: March 1, 2021
    Publication date: June 24, 2021
    Applicant: Ablynx N.V.
    Inventor: Marie-Ange Buyse
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20210188965
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: December 9, 2020
    Publication date: June 24, 2021
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • Polypeptides and polypeptide constructs comprising single domain antibodies directed against von willebrand factor
    Patent number: 11034755
    Abstract: The present invention relates to polypeptides comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, gpIb and/or collagen, homologues of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation and which overcomes the problems of the prior art. A further aspect of the invention is methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g. PCTA, stenting), methods and kits for screening for agents that modulate platelet-mediated aggregation and kits for the diagnosis of diseases related to platelet-mediated aggregation.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: June 15, 2021
    Assignee: Ablynx N.V.
    Inventor: Karen Silence
  • Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
    Patent number: 11028151
    Abstract: Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: June 8, 2021
    Assignee: Ablynx N.V.
    Inventors: Erik Depla, Catelijne Stortelers, Stephanie Staelens
  • Nanobody dimers linked via C-terminally engineered cysteins
    Patent number: 11021544
    Abstract: The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: June 1, 2021
    Assignee: Ablynx N.V.
    Inventors: Carlo Boutton, Daniel Janssen, Peter Casteels, Peter Schotte, Francis Descamps
  • Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
    Patent number: 11009511
    Abstract: Described herein are methods, assays and techniques for detecting and/or measuring anti-drug antibodies that bind to a protein, polypeptide or other compound or molecule that comprises at least one immunoglobulin variable domain with an exposed C-terminal region.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: May 18, 2021
    Assignee: Ablynx N.V.
    Inventors: Veerle Snoeck, Marie-Ange Buyse, Judith Baumeister
  • Pharmaceutical compositions comprising a polypeptide that binds to IL-6
    Patent number: 11008393
    Abstract: Methods are provided for the treatment of IL-6R related diseases. More specifically, specific dose regimens and pre-filled syringes are provided for subcutaneous administration, to subjects suffering an IL-6R related disease, of immunoglobulin single variable domains that bind IL-6R.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: May 18, 2021
    Assignee: Ablynx N.V.
    Inventors: Sven Hoefman, Maria-Laura Sargentini-Maier, Katrien Van Beneden